Cart
Products
Utilization of MBD-Seq to Elucidate Differentially Methylated Regions in cfDNA Across Healthy and Cancer Patients
The 5-Methylcytosine (5-mC) epigenetic DNA modification alters gene expression and genome metabolism, and its deregulation is associated with many human diseases. Cell-Free DNA (cfDNA) released from apoptotic cells has recently gained attention, as mutations or epimutations (e.g. 5-mC variations) detected in cfDNA were shown to have high diagnostic potential to assess the presence, stage and outcome of several cancers. However, 5-mC detection in cfDNA remains a challenge as input material is often very scarce. MBD-Seq is a method that leverages the ability of Methyl-CpG-binding domain protein 2 (MBD2) to capture and detect highly methylated regions of DNA genome-wide. This AACR 2024 poster demonstrates use of MBD-Seq for the detection of aberrant methylation patterns in cfDNA from healthy and diseased patients, finding it to be specific and sensitive, revealing striking differences in methylation of key tumor-associated genes.
Please note: The submission form below may not display on all browsers. For best results, we recommend using Chrome or Safari as your web browser. If you are having problems accessing the form, please contact technical support.
